Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

Leptin receptor antagonist peptide demonstrates efficacy against triple negative breast cancer

A new peptide developed by researchers in Temple University's College of Science and Technology has demonstrated efficacy against triple negative breast cancer.

1 Mar 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

New guidelines recommend routine use of allergy tests to improve quality of care in children

The first guidelines for food allergy in children and young people issued by NICE, National Institute for health and Clinical Excellence, recommend routine use of allergy tests in NHS primary care and community settings to confirm suspected food allergy.

24 Feb 2011

Allergan receives FDA approval for expanded use of LAP-BAND System in obese adults

Allergan, today announced the U.S. Food and Drug Administration approved the expanded use of the LAP-BAND System, Allergan's gastric band, for adults with obesity who have failed more conservative weight reduction alternatives, such as diet and exercise and pharmacotherapy, and have a Body Mass Index of 30-40 and at least one obesity related comorbid condition.

16 Feb 2011

Idera: IMO-3100 in lupus preclinical model suppressed several key disease progression parameters

Idera Pharmaceuticals, Inc. announced today that it is presenting data on IMO-3100, an antagonist of TLR7 and TLR9, in a preclinical model of lupus showing that treatment with IMO-3100 suppressed several key disease progression parameters.

15 Feb 2011

Blocking interleukin 15 may help restore oral tolerance to gluten

Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.

11 Feb 2011

NIAID doctor receives Will Rogers Institute's award for outstanding contributions to lung research

The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.

10 Feb 2011

Karo Bio fourth quarter net loss increases to MSEK 50.1

The January - December period and fourth quarter 2010 in brief

9 Feb 2011

Sun exposure reduces risk of multiple sclerosis: Study

A new Australian study has found that increased sun exposure and higher vitamin D levels may help to protect against the risk of developing multiple sclerosis (MS).

8 Feb 2011

PDL, UCB enter definitive settlement agreement to resolve all legal patent disputes

UCB SA, on behalf of its affiliate UCB Pharma S.A., and PDL BioPharma, today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia, and PDL's patents known as the Queen et al. patents.

8 Feb 2011

The Lancet journal publishes BENLYSTA BLISS-52 study against SLE

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.

7 Feb 2011

Researchers identify regulatory defect that drives lupus

Researchers at Dana-Farber Cancer Institute in Cambridge, Mass., in collaboration with Jackson Laboratory scientists, have identified a regulatory defect that drives lupus.

4 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Researchers discover 'common set of dysregulated miRNAs in murine lupus models'

Potentially impacting future diagnosis and treatment of lupus, an immune illness affecting more than 5 million people worldwide, researchers at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech have likely uncovered where the breakdown in the body's lymphocyte molecular regulatory machinery is occurring.

1 Feb 2011

PPTA offers new DVD on plasma donation

Anyone curious about what to expect as a plasma donor and how plasma contributes to lifesaving medicines can now learn about the process thanks to a new DVD from the Plasma Protein Therapeutics Association.

29 Jan 2011

LFA launches new nationwide education series for people with lupus

The Lupus Foundation of America has launched a new nationwide education series, Lupus: Learn from the Experts, designed to provide people with lupus essential information about living with lupus from some of the world's leading lupus experts. The program is a series of teleconferences hosted by a lupus expert, and will cover a wide variety of topics important to people with lupus, including disability, kidney involvement, and clinical trials.

29 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

27 Jan 2011

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

Researchers in China have demonstrated interferon-alpha (IFN-α) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE). For the first time, IFN-α priming was shown to promote lipid uptake and foam cell formation—a crucial step in plaque build-up. This activation of the IFN signaling pathway may be linked to the premature atherosclerosis risk in SLE.